Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes

Administration of low-dose interleukin-2 (IL-2) alone or combined with rapamycin (RAPA) prevents hyperglycemia in NOD mice. Also, low-dose IL-2 cures recent-onset type 1 diabetes (T1D) in NOD mice, partially by boosting pancreatic regulatory T cells (T(reg) cells). These approaches are currently bei...

Descripción completa

Detalles Bibliográficos
Autores principales: Baeyens, Audrey, Pérol, Louis, Fourcade, Gwladys, Cagnard, Nicolas, Carpentier, Wassila, Woytschak, Janine, Boyman, Onur, Hartemann, Agnès, Piaggio, Eliane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749335/
https://www.ncbi.nlm.nih.gov/pubmed/23670972
http://dx.doi.org/10.2337/db13-0214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749335/
https://www.ncbi.nlm.nih.gov/pubmed/23670972
http://dx.doi.org/10.2337/db13-0214

Ejemplares similares